CSPHF

CStone Pharmaceuticals

CSPHF, USA

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma. The company's products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.

https://www.cstonepharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CSPHF
stock
CSPHF

High Growth Tech Stocks In Asia To Watch This July 2025 Yahoo Finance

Read more →

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

2.87

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-42.88 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.33 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.78

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of CStone Pharmaceuticals

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2021-03-31

EPS Actual

-0.0519

EPS Estimate

0

EPS Difference

-0.0519

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.